AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Anticancer drug developer announces second quarter 2002 financial results.(Brief Article)
2002 OCT 3 - (NewsRx.com & NewsRx.net) -- NeoPharm, Inc., (NEOL) announced financial results for the second quarter of 2002. The company reported a net loss of $9,019,674 or $0.55 per share, basic and diluted, for the second quarter 2002 versus a net loss of $2,506,542 or $0.16 per share, basic and diluted, during the second quarter of 2001.
For the first half of 2002, the company reported a net loss of $14,823,637, or $0.91 per share basic and diluted, compared with first half 2001 net loss of $3,090,369, or $0.19 per share basic and diluted. Total cash and marketable securities on hand at June 30, 2002 was $110,724,116.
The company expects that the net loss for 2002 will be between $1.84-2.00 per share, or between $30-32.5 million, in line with the company's previous estimate. The increase in the net loss for the second quarter of 2002 versus the same period in 2001 was primarily the result of an increase in research and development expenses as the company moved its four drugs in phase I/II clinical trials towards phase II/III clinical trials.
As progress was made in phase I clinical trials, the company incurred research and development expenses related to production of phase II drug supply during the second quarter of 2002 which had been previously scheduled for the third quarter of 2002. In addition, under a license agreement entered into in 1999 with Pharmacia Corp., the company incurred expenses during the first half of 2002 related to its efforts to develop an easy-to-use neolipid formulation for Liposome Encapsulated Paclitaxel (LEP). Under the terms of the license agreement, NeoPharm is entitled to be reimbursed for these expenses.
...- POZEN Inc. Releases Third-Quarter Results; Begins Two Clinical Trials.
- Press release article from: PR Newswire October 25, 2001 700+ words
...three Phase III clinical trials nearing completion. POZEN's net loss attributable to...basic and diluted net loss per common share and pro forma net loss per common share...two significant clinical trials in the third quarter...
- KeraVision, Inc. releases six month financial statement; investigational...
- Press release article from: Business Wire September 14, 1995 700+ words
...to higher costs for clinical trials and patent coverage...related technology. The net loss for the second quarter...currently in FDA Phase II clinical trials. -0- Condensed Statement...expense -- -- -- (60) Net loss $(1,556) $(2...
- San Antonio Pharmaceutical Firm Reports Net Loss of $62.1 Million.
- Newspaper article from: San Antonio Express-News (San Antonio, TX) January 28, 2004 700+ words
...a former client, the net loss for 2003 would have been...quarter, Ilex reported a net loss of $17.8 million on...money into additional clinical trials on Campath and several other drugs, 2004's net loss is expected to top...
- Cardiovascular drug maker reports a net loss of $5.2M.
- Newspaper article from: Biotech Week December 18, 2002 700+ words
...SAPPHIRE and SILVER clinical trials. For the 9 months...Alteon had a net loss of $13,799...SAPPHIRE and SILVER clinical trials. The noncash...861,000. The net loss for both the...SAPPHIRE and SILVER clinical trials of ALT-711...
- deCODE's FY 2006 net loss deepens 36.1%.(Financial report)
- Newspaper article from: Pharma Marketletter March 19, 2007 700+ words
...However, its net loss worsened to $85...to the cost of clinical trials in the company...Basic and diluted net loss per share was...predictions, though net loss exceeded their...reflecting the cost of clinical trials in its heart attack...
- Pharmaceutical company reports net loss of $4.4M.
- Newspaper article from: Biotech Week December 25, 2002 700+ words
...related to funding clinical trials, expanding research...actively engaged in clinical trials. We expect our operating...when we begin human clinical trials, which are targeted...half of 2003." The net loss for the 9 months ended...
- Radiance Reports 41 Percent Increase in Revenues and 42 Percent Reduction in...
- Press release article from: Business Wire July 20, 2000 700+ words
...The decrease in net loss for the second...higher spending for clinical trials and research and...the company's net loss was $2,618...decrease in the net loss for the first six...though spending for clinical trials and research and...
- ENDOVASCULAR TECHNOLOGIES ANNOUNCES FIRST QUARTER 1996 FINANCIAL RESULTS...
- Press release article from: PR Newswire April 17, 1996 700+ words
...944 as compared to a net loss of $2,061,370 for the first quarter of 1995. Net loss per share of $0.35...1996 compares to a net loss per share of $0.33...includes the cost of clinical trials. EVT's cash, cash...
Source: HighBeam Research, Anticancer drug developer announces second quarter 2002 financial...